FR2986232B1 - Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique - Google Patents

Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique

Info

Publication number
FR2986232B1
FR2986232B1 FR1250768A FR1250768A FR2986232B1 FR 2986232 B1 FR2986232 B1 FR 2986232B1 FR 1250768 A FR1250768 A FR 1250768A FR 1250768 A FR1250768 A FR 1250768A FR 2986232 B1 FR2986232 B1 FR 2986232B1
Authority
FR
France
Prior art keywords
preparation
bicyclic heterocyclic
therapeutic application
heterocyclic derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1250768A
Other languages
English (en)
Other versions
FR2986232A1 (fr
Inventor
Alain Braun
Olivier Crespin
Yann Foricher
Gilbert Marciniak
Nicolas Muzet
Eric Nicolai
Cecile Pascal
Bertrand Vivet
Fabrice Viviani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR1250768A priority Critical patent/FR2986232B1/fr
Priority to ARP130100196A priority patent/AR089782A1/es
Priority to CN201380016539.XA priority patent/CN104203958B/zh
Priority to BR112014018226A priority patent/BR112014018226A8/pt
Priority to UY0001034594A priority patent/UY34594A/es
Priority to CA2862747A priority patent/CA2862747A1/fr
Priority to HRP20170288TT priority patent/HRP20170288T1/hr
Priority to LTEP13712331.1T priority patent/LT2807172T/lt
Priority to PT137123311T priority patent/PT2807172T/pt
Priority to ES13712331.1T priority patent/ES2617880T3/es
Priority to HUE13712331A priority patent/HUE031917T2/en
Priority to US14/374,838 priority patent/US9120812B2/en
Priority to KR1020147023238A priority patent/KR20140125389A/ko
Priority to PCT/IB2013/050656 priority patent/WO2013111106A1/fr
Priority to PL13712331T priority patent/PL2807172T3/pl
Priority to RU2014134640A priority patent/RU2627269C2/ru
Priority to AU2013213261A priority patent/AU2013213261B2/en
Priority to DK13712331.1T priority patent/DK2807172T3/en
Priority to MX2014009084A priority patent/MX348841B/es
Priority to SI201330547A priority patent/SI2807172T1/sl
Priority to JP2014553846A priority patent/JP6068508B2/ja
Priority to EP13712331.1A priority patent/EP2807172B1/fr
Priority to SG11201404325VA priority patent/SG11201404325VA/en
Priority to TW102102986A priority patent/TWI572608B/zh
Publication of FR2986232A1 publication Critical patent/FR2986232A1/fr
Application granted granted Critical
Publication of FR2986232B1 publication Critical patent/FR2986232B1/fr
Priority to IL233774A priority patent/IL233774A/en
Priority to CY20171100270T priority patent/CY1118852T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR1250768A 2012-01-26 2012-01-26 Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique Expired - Fee Related FR2986232B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR1250768A FR2986232B1 (fr) 2012-01-26 2012-01-26 Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
ARP130100196A AR089782A1 (es) 2012-01-26 2013-01-23 Derivados heterociclicos biciclicos, su preparacion y su aplicacion en terapeutica
AU2013213261A AU2013213261B2 (en) 2012-01-26 2013-01-25 Pyrimidooxazocine derivatives as mTOR - inhibitors
UY0001034594A UY34594A (es) 2012-01-26 2013-01-25 Derivados heterocíclicos bicíclicos, su preparación y su aplicación en terapéutica
CA2862747A CA2862747A1 (fr) 2012-01-26 2013-01-25 Derives de pyrimidooxazocine utiles comme inhibiteurs de mtor
HRP20170288TT HRP20170288T1 (hr) 2012-01-26 2013-01-25 DERIVATI PIRIMIDOOKSAZOCINA KAO INHIBITORI mTOR
LTEP13712331.1T LT2807172T (lt) 2012-01-26 2013-01-25 Pirimidooksazocino dariniai kaip mtor slopikliai
PT137123311T PT2807172T (pt) 2012-01-26 2013-01-25 Derivados de pirimidooxazocina como inibidores de mtor
ES13712331.1T ES2617880T3 (es) 2012-01-26 2013-01-25 Derivados de pirimidooxazocina como inhibidores de mTOR
HUE13712331A HUE031917T2 (en) 2012-01-26 2013-01-25 Pyrimidooxazocin derivatives as mTOR inhibitors
US14/374,838 US9120812B2 (en) 2012-01-26 2013-01-25 Pyrimidooxazocine derivatives as mTOR-inhibitors
KR1020147023238A KR20140125389A (ko) 2012-01-26 2013-01-25 Mtor-저해제로서 피리미도옥사조신 유도체
PCT/IB2013/050656 WO2013111106A1 (fr) 2012-01-26 2013-01-25 DÉRIVÉS DE PYRIMIDOOXAZOCINE UTILES COMME INHIBITEURS DE mTOR
PL13712331T PL2807172T3 (pl) 2012-01-26 2013-01-25 Pochodne pirymidooksazocyny jako inhibitory mTOR
CN201380016539.XA CN104203958B (zh) 2012-01-26 2013-01-25 二环杂环衍生物、其制备及治疗用途
MX2014009084A MX348841B (es) 2012-01-26 2013-01-25 Derivados de pirimidooxazocina como inhibidores de mtor.
EP13712331.1A EP2807172B1 (fr) 2012-01-26 2013-01-25 DÉRIVÉS DE PYRIMIDOOXAZOCINE UTILES COMME INHIBITEURS DE mTOR
DK13712331.1T DK2807172T3 (en) 2012-01-26 2013-01-25 PYRIMIDOOXAZOCINE DERIVATIVES AS MTOR INHIBITORS
SI201330547A SI2807172T1 (sl) 2012-01-26 2013-01-25 Derivati pirimidooksazocina kot inhibitorji MTOR
JP2014553846A JP6068508B2 (ja) 2012-01-26 2013-01-25 Ｍｔｏｒ阻害剤としてのピリミドオキサゾシン誘導体
BR112014018226A BR112014018226A8 (pt) 2012-01-26 2013-01-25 Derivados de pirimidooxazocina como inibidores de mtor
SG11201404325VA SG11201404325VA (en) 2012-01-26 2013-01-25 Pyrimidooxazocine derivatives as mtor - inhibitors
TW102102986A TWI572608B (zh) 2012-01-26 2013-01-25 雙環雜環衍生物、其製備方法及醫療用途
RU2014134640A RU2627269C2 (ru) 2012-01-26 2013-01-25 Бициклические гетероциклические производные, их получение и применение
IL233774A IL233774A (en) 2012-01-26 2014-07-23 Pyrimidooxazocine derivatives as mtor-inhibitors
CY20171100270T CY1118852T1 (el) 2012-01-26 2017-02-28 Παραγωγα πυριμιδοοξαζοσινης ως αναστολεις της mtor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250768A FR2986232B1 (fr) 2012-01-26 2012-01-26 Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2986232A1 FR2986232A1 (fr) 2013-08-02
FR2986232B1 true FR2986232B1 (fr) 2014-02-14

Family

ID=47997597

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1250768A Expired - Fee Related FR2986232B1 (fr) 2012-01-26 2012-01-26 Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique

Country Status (26)

Country Link
US (1) US9120812B2 (fr)
EP (1) EP2807172B1 (fr)
JP (1) JP6068508B2 (fr)
KR (1) KR20140125389A (fr)
CN (1) CN104203958B (fr)
AR (1) AR089782A1 (fr)
AU (1) AU2013213261B2 (fr)
BR (1) BR112014018226A8 (fr)
CA (1) CA2862747A1 (fr)
CY (1) CY1118852T1 (fr)
DK (1) DK2807172T3 (fr)
ES (1) ES2617880T3 (fr)
FR (1) FR2986232B1 (fr)
HR (1) HRP20170288T1 (fr)
HU (1) HUE031917T2 (fr)
IL (1) IL233774A (fr)
LT (1) LT2807172T (fr)
MX (1) MX348841B (fr)
PL (1) PL2807172T3 (fr)
PT (1) PT2807172T (fr)
RU (1) RU2627269C2 (fr)
SG (1) SG11201404325VA (fr)
SI (1) SI2807172T1 (fr)
TW (1) TWI572608B (fr)
UY (1) UY34594A (fr)
WO (1) WO2013111106A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831722B (zh) 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
CN107001317B (zh) * 2014-09-29 2019-05-24 山东轩竹医药科技有限公司 高选择性取代嘧啶类pi3k抑制剂
US10307707B2 (en) * 2017-05-17 2019-06-04 Thomas P. Daly 1-amino-2-methyl-2-propanol derivatives
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition
WO2026154417A1 (fr) * 2025-01-17 2026-07-23 Pfizer Inc. Composés amide/sulfonamide hétérocycliques fusionnés utilisés en tant qu'agonistes des récepteurs de la calcitonine/amyline pour le traitement de l'obésité

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100887471B1 (ko) * 2002-01-18 2009-03-10 교린 세이야꾸 가부시키 가이샤 축합 바이사이클릭 피리미딘 유도체
EP1562956A4 (fr) * 2002-11-22 2007-10-10 Japan Tobacco Inc Heterocycles contenant de l'azote bicyclique fusionne
KR20110098908A (ko) * 2008-11-11 2011-09-02 엑스커버리 홀딩 컴퍼니 엘엘씨 ＰＩ3Ｋ/ｍＴＯＲ 키나제 억제제
MX2011012584A (es) * 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
JP2013529212A (ja) * 2010-05-19 2013-07-18 エクスカバリー ホールディング カンパニー，エルエルシー ｍＴＯＲ選択的キナーゼ阻害剤

Also Published As

Publication number Publication date
HRP20170288T1 (hr) 2017-04-21
EP2807172A1 (fr) 2014-12-03
BR112014018226A2 (fr) 2017-06-20
RU2627269C2 (ru) 2017-08-04
US20140378433A1 (en) 2014-12-25
LT2807172T (lt) 2017-03-27
AU2013213261B2 (en) 2017-07-20
TW201333016A (zh) 2013-08-16
SG11201404325VA (en) 2014-08-28
SI2807172T1 (sl) 2017-03-31
TWI572608B (zh) 2017-03-01
EP2807172B1 (fr) 2016-11-30
US9120812B2 (en) 2015-09-01
CN104203958B (zh) 2017-05-31
MX348841B (es) 2017-06-30
PT2807172T (pt) 2017-03-06
PL2807172T3 (pl) 2017-05-31
DK2807172T3 (en) 2017-03-06
FR2986232A1 (fr) 2013-08-02
MX2014009084A (es) 2015-02-05
UY34594A (es) 2013-09-02
JP6068508B2 (ja) 2017-01-25
CN104203958A (zh) 2014-12-10
RU2014134640A (ru) 2016-03-27
HUE031917T2 (en) 2017-08-28
KR20140125389A (ko) 2014-10-28
IL233774A (en) 2016-06-30
AR089782A1 (es) 2014-09-17
JP2015504914A (ja) 2015-02-16
BR112014018226A8 (pt) 2017-07-11
ES2617880T3 (es) 2017-06-20
CY1118852T1 (el) 2018-01-10
WO2013111106A1 (fr) 2013-08-01
AU2013213261A1 (en) 2014-08-21
CA2862747A1 (fr) 2013-08-01

Similar Documents

Publication Publication Date Title
LTC2822953I2 (lt) Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
FR2963007B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
LT2770994T (lt) 1h-pirazolo[3,4-b]piridinai ir jų terapiniai panaudojimai
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
IL230786A0 (en) Heterocyclic derivative and pharmaceutical drug
LT2729151T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
HUE053688T2 (hu) Biciklusos heterociklusos vegyületek és ezek terápiában történõ alkalmazása
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
IL229963A0 (en) Substituted quinolines and their use as medicaments
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
FR2974576B1 (fr) Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
PL2922576T3 (pl) Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
CO6910193A2 (es) Derivados de anilina, su preparación y su aplicación terapéutica
IL234606B (en) Novel methods and composition for treatment of disease
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
IL243227A0 (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
FR2967672B1 (fr) Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
EP2789607A4 (fr) Dérivé de pyridone et médicament le contenant
ZA201501597B (en) Macrolide derivatives,preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20200910